PL401116A1 - Composition added to infusion fluids - Google Patents

Composition added to infusion fluids

Info

Publication number
PL401116A1
PL401116A1 PL401116A PL40111612A PL401116A1 PL 401116 A1 PL401116 A1 PL 401116A1 PL 401116 A PL401116 A PL 401116A PL 40111612 A PL40111612 A PL 40111612A PL 401116 A1 PL401116 A1 PL 401116A1
Authority
PL
Poland
Prior art keywords
amount
composition
fluids
metal compounds
infusion
Prior art date
Application number
PL401116A
Other languages
Polish (pl)
Inventor
Florian Ryszka
Barbara Dolińska
Lucyna Leszczyńska
Lech Cierpka
Zdzisław Smorąg
Original Assignee
Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa filed Critical Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa
Priority to PL401116A priority Critical patent/PL401116A1/en
Priority to EP13780230.2A priority patent/EP2906234A1/en
Priority to PCT/PL2013/000118 priority patent/WO2014058329A1/en
Publication of PL401116A1 publication Critical patent/PL401116A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest kompozycja dodawana do płynów infuzyjnych w szczególności do płynów do przeszczepu, do osocza, do wlewu lub do dializy nerek stosowanych w transplantacji, a także do preparatów krwi i krwiopochodnych oraz płynów stosowanych w dializie otrzewnowej. Kompozycja zawiera w swoim składzie hormony: prolaktynę w ilości od 1,0 ng/l do 10 µg/l lub somatotropinę w ilości od 10 ng/l do 10,0 µg/l lub choriogonadotropinę w ilości od 1,0 ng/l do 1,0 µg/l lub lutropinę w ilości od 10 ng/l do 100,0 µg/l lub folikulotropinę w ilości od 0,01 µg/l do 1,0 µg/l lub buserelinę w ilości od 0,001 µg/l do 1 µg/l. Odmianą jest kompozycja według wynalazku, która zawiera w swoim składzie związki metali takie jak selen lub mangan lub cynk w ilości od 0,0 1 µg/l do 10,0 µg/l. Hormon i związki metali takie jak selen lub mangan rozpuszczony jest w 1-5% roztworze kwasu askorbinowego lub 1-5% roztworze L-cysteiny w warunkach jałowych o pH do wartości 3,5. Hormon i związki metali rozpuszczone w roztworze kwasu askorbinowego i cysteiny przygotowane w warunkach sterylnych w fiolkach są dodawane do znanych płynów przed ich użyciem.The subject of the invention is a composition added to infusion fluids, in particular to transplant fluids, plasma, infusion or kidney dialysis used in transplantation, as well as blood and blood preparations and fluids used in peritoneal dialysis. The composition contains the hormones: prolactin in an amount from 1.0 ng / l to 10 µg / l or somatotropin in an amount from 10 ng / l to 10.0 µg / l or choriogonadotropin in an amount from 1.0 ng / l to 1.0 µg / l or lutropin in the amount from 10 ng / l to 100.0 µg / l or follitropin in the amount from 0.01 µg / l to 1.0 µg / l or buserelin in the amount from 0.001 µg / l to 1 µg / l. A variation is the composition according to the invention which contains in its composition metal compounds such as selenium or manganese or zinc in an amount from 0.0 1 µg / l to 10.0 µg / l. Hormone and metal compounds such as selenium or manganese are dissolved in a 1-5% ascorbic acid solution or 1-5% L-cysteine solution under sterile conditions with a pH value of up to 3.5. Hormone and metal compounds dissolved in a solution of ascorbic acid and cysteine prepared under sterile conditions in vials are added to known liquids before use.

PL401116A 2012-10-09 2012-10-09 Composition added to infusion fluids PL401116A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL401116A PL401116A1 (en) 2012-10-09 2012-10-09 Composition added to infusion fluids
EP13780230.2A EP2906234A1 (en) 2012-10-09 2013-09-20 Compositions based on hypophyseal hormones for adding to infusion fluids
PCT/PL2013/000118 WO2014058329A1 (en) 2012-10-09 2013-09-20 Compositions based on hypophyseal hormones for adding to infusion fluids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401116A PL401116A1 (en) 2012-10-09 2012-10-09 Composition added to infusion fluids

Publications (1)

Publication Number Publication Date
PL401116A1 true PL401116A1 (en) 2014-04-14

Family

ID=49474668

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401116A PL401116A1 (en) 2012-10-09 2012-10-09 Composition added to infusion fluids

Country Status (3)

Country Link
EP (1) EP2906234A1 (en)
PL (1) PL401116A1 (en)
WO (1) WO2014058329A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL423936A1 (en) * 2017-12-18 2019-07-01 Biochefa Farmaceutyczny Zakład Naukowo-Produkcyjny Spółka Z Ograniczoną Odpowiedzialnością Fluid for perfusion and organ preservation and method for producing it

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014264537B2 (en) * 2013-05-08 2018-10-18 Gambro Lundia Ab Dialysis formulation
CN112569340A (en) * 2020-12-31 2021-03-30 苏州素仕生物科技有限公司 Sterile buserelin injection and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL205012A1 (en) 1978-03-01 1979-11-19 Polski Komitet Normalizacji I METHOD OF CHECKING HIGH-LOAD TRIGGER SCALES AND THE TEST DEVICE TO USE THIS METHOD
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
EP1938821B1 (en) * 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
EP1812047A4 (en) 2004-10-07 2010-08-04 Stem Cell Therapeutics Corp Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
WO2010084384A1 (en) * 2009-01-26 2010-07-29 Lola Maksumova Combinations of an antiplatelet agent and an antioxidant for the treatment of vascular disorders
RU2423987C1 (en) * 2009-12-31 2011-07-20 Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО СПХФА Росздрава) Infusion solution for total blood volume replacement, hydro-electrolytic rebalancing and hematopoiesis process normalisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL423936A1 (en) * 2017-12-18 2019-07-01 Biochefa Farmaceutyczny Zakład Naukowo-Produkcyjny Spółka Z Ograniczoną Odpowiedzialnością Fluid for perfusion and organ preservation and method for producing it

Also Published As

Publication number Publication date
WO2014058329A1 (en) 2014-04-17
EP2906234A1 (en) 2015-08-19
WO2014058329A8 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
PH12018502670A1 (en) Stable liquid pharmaceutical preparation
EA201992155A1 (en) METHODS OF CRYOGENIC STORAGE
EP4272763A3 (en) Liquid protein formulations containing organophosphates
EA201790989A1 (en) STABLE PREPARATION OF PROTEIN SOLUTION CONTAINING ANTI-VEGF ANTIBODY IN HIGH CONCENTRATION
PH12014502778B1 (en) Antibody formulation
MX2019003611A (en) Novel formulations.
EA201490817A1 (en) ETANERCEPT COMPOSITIONS STABILIZED BY METAL IONS
PL401116A1 (en) Composition added to infusion fluids
PH12015501602A1 (en) Agent for elevating nitric oxide concentration
MX2019006107A (en) Arsenic compositions.
PH12016501117A1 (en) Pharmaceutical compositions of carotenoid
EA201590032A1 (en) LOW-TOXIC STAGGER AND METHODS OF ITS APPLICATION
PL408686A1 (en) Composition added to the infusion fluids
PL413307A1 (en) Stabilizing composition for stabilization of silty and clay grounds, method for producing it and method for stabilization of silty and clay grounds
EA201691528A1 (en) WATER COMPOSITION CONTAINING OLIGODYNAMIC METAL
TN2017000232A1 (en) Injectable formulations of paracetamol
EA201792502A1 (en) KABAZITAXEL AND ITS APPLICATIONS FOR CANCER TREATMENT
Kim Determination of Heavy Metals in Sea Salt Using Anodic Stripping Voltammetry
PL413830A1 (en) Lactoferrin with manganese ions complex, method for obtaining it, application of the complex and pharmaceutical composition containing the complex of lactoferrin and manganese ions
Rizk Various toxicities: case report
PL413320A1 (en) Stabilizing composition for stabilization of silty and clay grounds
PL412243A1 (en) Applications of chiral ionic liquids containing the derivative of (1R,2S,5R)-(-)-menthol
PL412686A1 (en) Diluent for rabbit semen and the semen thinned by this diluent
PE20191462A1 (en) LIQUID COMPOSITION CONTAINING PRADOFLOXACIN
Goncharuk THE ROLE OF PHYSICAL PERFECTION IN PERSONAL DEVELOPMENT

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 408686

Country of ref document: PL

Kind code of ref document: A1